CTOs on the Move

Dyne Therapeutics

www.dyne-tx.com

 
Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dyne-tx.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.786.8230

Executives

Name Title Contact Details
Suhas Mulki
Senior Information Security Engineer Profile

Funding

Dyne Therapeutics raised $50M on 04/03/2019
Dyne Therapeutics raised $115M on 08/10/2020
Dyne Therapeutics raised $168M on 01/21/2021

Similar Companies

Nano-C

Nano-C is a Westwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AmCyte

AmCyte Inc. is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genyous Life Sciences

Genyous Life Sciences is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gen Trak (Main)

Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.